DG DISPATCH - APA: Bupropion and Hypoactive Sexual Desire Disorder
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - APA: Bupropion and Hypoactive Sexual Desire Disorder

By Lara Pullen

Special to DG News

CHICAGO, IL -- May 19, 2000 -- Bupropion sustained release (SR) may be an effective treatment for hypoactive sexual desire disorder (HSDD) in non-depressed women.

At the 2000 Annual Meeting of the American Psychiatric Association, in Chicago, IL, R. Taylor Segraves, MD, and Kathleen B. Segraves, MD, both of Case Western Reserve University, Cleveland, OH, presented the results of a multicenter, single-blind study designed to test the safety and efficacy of bupropion SR.

The study included a four-week placebo phase followed by an eight-week treatment phase. Non-depressed women (n=51) were at least 20 years of age with a diagnosis of HSDD for at least the preceding six months as defined in the Diagnostic and Statistical Manual (DSM)-IV.

The following variables were assessed at each biweekly clinic visit (beginning at day 0): Investigator-Rated Sexual Desire and Sexual Functioning Assessments, Clinical Global Impressions Scale for Improvement of Illness (CGI-I), and Clinical Global Impressions Scale for Severity of Illness (CGI-S).

Of the 51 women who continued into the treatment phase, 15 (29 percent) were considered to be responders, with response seen as early as two weeks after beginning treatment. In addition, bupropion SR was generally well-tolerated.

Dr. Kathleen Segraves believes that further study is warranted and explained, "that we saw anything in that short amount of time is excellent."

Related links: Bupropion.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities